Literature DB >> 2434613

High protection of animals lethally infected with influenza virus by aprotinin-rimantadine combination.

O P Zhirnov.   

Abstract

The successful therapeutic synergism of aprotinin and rimantadine, which are known to attack different viral targets, was demonstrated in influenza-virus-infected animals. Combined treatment with these drugs of mice infected with a highly lethal dose of mouse-adapted influenza virus prevented the development of fatal haemorrhagic pneumonia and protected about 75% of animals; whereas the separate administration of aprotinin and rimantadine induced 35% and 15% protection, respectively.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2434613      PMCID： PMC7166978          DOI： 10.1002/jmv.1890210208

Source DB:  PubMed          Journal:  J Med Virol        ISSN： 0146-6615            Impact factor:   2.327


  30 in total

1.  Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide.

Authors:  S G Lazarowitz; P W Choppin
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

2.  Inhibition of fibrinolytic and thromboplastic activity by Trasylol.

Authors:  C J Amris
Journal:  Scand J Haematol       Date:  1966

3.  Hong Kong influenza: clinical, microbiologic, and pathologic features in 127 cases.

Authors:  M I Lindsay; E C Herrmann; G W Morrow; A L Brown
Journal:  JAMA       Date:  1970-12-07       Impact factor: 56.272

4.  Recombination of influenza A strains with fowl plague virus can change pneumotropism for mice to a generalized infection with involvement of the central nervous system.

Authors:  A Vallbracht; C Scholtissek; B Flehmig; H J Gerth
Journal:  Virology       Date:  1980-12       Impact factor: 3.616

Review 5.  [The phenomenon of proteolytic activation of myxoviruses and a new strategy for treating viral diseases].

Authors:  O P Zhirnov
Journal:  Vopr Virusol       Date:  1983 Jul-Aug

6.  Suppression of influenza virus replication in infected mice by protease inhibitors.

Authors:  O P Zhirnov; A V Ovcharenko; A G Bukrinskaya
Journal:  J Gen Virol       Date:  1984-01       Impact factor: 3.891

7.  Leupeptin inhibits retrovirus infection in mouse fibroblasts.

Authors:  K B Andersen
Journal:  J Virol       Date:  1983-12       Impact factor: 5.103

8.  On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride.

Authors:  J J Skehel; A J Hay; J A Armstrong
Journal:  J Gen Virol       Date:  1978-01       Impact factor: 3.891

9.  Inhibition of influenza virus uncoating by rimantadine hydrochloride.

Authors:  W C Koff; V Knight
Journal:  J Virol       Date:  1979-07       Impact factor: 5.103

10.  [Antiviral and therapeutic action of protease inhibitors in viral infections: experimental and clinical observations].

Authors:  O P Zhirnov; A V Ovcharenko; A G Bukrinskaia; L P Ursaki; L A Ivanova
Journal:  Vopr Virusol       Date:  1984 Jul-Aug
View more
  8 in total

1.  Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin.

Authors:  Chia-Hsing Leu; Mei-Lin Yang; Nai-Hui Chung; Yen-Jang Huang; Yu-Chu Su; Yi-Cheng Chen; Chia-Cheng Lin; Gia-Shing Shieh; Meng-Ya Chang; Shainn-Wei Wang; Yao Chang; Julie Chao; Lee Chao; Chao-Liang Wu; Ai-Li Shiau
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

2.  Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.

Authors:  Elena A Govorkova; Hong-Bin Fang; Ming Tan; Robert G Webster
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  Cleavage of influenza a virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases.

Authors:  Oleg P Zhirnov; Mine R Ikizler; Peter F Wright
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

4.  Replication of influenza B virus in chicken embryos is suppressed by exogenous aprotinin.

Authors:  O P Zhirnov; P B Golyando; A V Ovcharenko
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

5.  Combination chemotherapy for influenza.

Authors:  Elena A Govorkova; Robert G Webster
Journal:  Viruses       Date:  2010-07-27       Impact factor: 5.818

Review 6.  The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.

Authors:  Lukas Wettstein; Frank Kirchhoff; Jan Münch
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

7.  Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice.

Authors:  Bastian Hatesuer; Stephanie Bertram; Nora Mehnert; Mahmoud M Bahgat; Peter S Nelson; Stefan Pöhlmann; Stefan Pöhlman; Klaus Schughart
Journal:  PLoS Pathog       Date:  2013-12-05       Impact factor: 6.823

8.  The Proteolytic Activation of (H3N2) Influenza A Virus Hemagglutinin Is Facilitated by Different Type II Transmembrane Serine Proteases.

Authors:  Nora Kühn; Silke Bergmann; Nadine Kösterke; Ruth L O Lambertz; Anna Keppner; Judith M A van den Brand; Stefan Pöhlmann; Siegfried Weiß; Edith Hummler; Bastian Hatesuer; Klaus Schughart
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.